BJMO - volume 12, issue 3, february 2018
B. De Laere PhD, Markus Mayrhofer , T. Whitington , P-J. Van Dam MD, P. Van Oyen , C. Ghysel , J. Ampe , P. Ost MD, PhD, Wim Demey MD, L. Hoekx MD, D. Schrijvers MD, PhD, B. Brouwers MD, PhD, W. Lybaert MD, E. Everaert , P. Van Kerckhove , D. De Maeseneer MD, M. Strijbos MD, PhD, A. Bols MD, PhD, K. Fransis , Nick Beije , Inge De Kruijff , S. Oeyen , A. Rutten MD, V. Van Dam , A. Brouwer , D. Goossens , Lien Heyrman , G. Van Den Eynden MD, PhD, J. Vandebroek , Jurgen Del-Favero , S. Sleijfer , A. Uhlen , Jeffrey Yachnin , S. Van Laere PhD, Henrik Grönberg , Johan Lindberg , L. Dirix MD
BJMO - volume 11, issue 2, march 2017
Ir A. Hébrant PhD, G. Froyen PhD, B. Maes MD, PhD, R. Salgado MD, PhD, M. Le Mercier PhD, N. D’Haene MD, PhD, S. De Keersmaecker PhD, K. Claes PhD, J. Van der Meulen MD, P. Aftimos MD, J. Van Houdt PhD, K. Cuppens MD, K. Vanneste PhD, E. Dequeker PhD, S. Van Dooren PhD, J. Van Huysse MD, F. Nollet PhD, S. Van Laere PhD, B. Denys MD, V. Ghislain , C. Van Campenhout PhD, M. Van den Bulcke PhD
Targeted next generation sequencing is a complex procedure including the ‘wet bench’ and ‘dry bench’ parts. Both parts are composed of many steps for which optimal assay conditions and settings must be determined.
The aim of these guidelines is to provide generic, platform independent, recommendations for targeted next generation sequencing tests to detect acquired somatic mutations in DNA, in (haemato)-oncology that are complementary to the ISO 15189 norm (medical laboratories) in order to:
(BELG J MED ONCOL 2017;11(2):56–67)
Read moreBJMO - 2017, issue 3, february 2017
B. De Laere PhD, P. Van Oyen , C. Ghysel , P. Ost MD, PhD, Wim Demey MD, L. Hoekx MD, D. Schrijvers MD, PhD, B. Brouwers MD, PhD, W. Lybaert MD, E. Everaert , J. Ampe , P. Van Kerckhove , D. De Maeseneer MD, M. Strijbos MD, PhD, A. Bols MD, PhD, K. Fransis , S. Oeyen , V. Van Dam , A. Brouwer , G. Van Den Eynden MD, PhD, A. Rutten MD, J. Vandebroek , S. Van Laere PhD, L. Dirix MD
BJMO - 2017, issue 3, february 2017
P-J. Van Dam MD, B. Galjart , P. De Paepe MD, PhD, T. Feryn , V. Duwel , L. Dirix MD, P. Vermeulen MD, S. Van Laere PhD
BJMO - 2017, issue 3, february 2017
A. Brouwer , P-J. Van Dam MD, E. Sluydts , M. Peeters MD, PhD, P. Vermeulen MD, S. Van Laere PhD, L. Dirix MD
BJMO - volume 6, issue 6, december 2012
M. Marsan , P. Neven MD, PhD, P. Vermeulen MD, L. Dirix MD, S. Van Laere PhD
TGF-β is a major regulator and driver of many biological processes, but its main function is inhibition of cell cycle progression and apoptosis, thus establishing a tumour-protective effect in early stages of malignant transformation. However, mutational alterations can occur at different levels of the TGF-β signaling cascade. These mutations, combined with the significant influence of the tumour microenvironment on this cascade, can cause a functional shift of TGF-β from being a tumour suppressor to becoming a tumour promoter in more advanced cancers. In most tumours this will ultimately contribute to the formation of metastatic laesions. In the clinical setting of breast cancer, TGF-β plays a significant role in the acquisition of endocrine resistance. Thus, therapeutic intervention of TGF-β signaling might deliver significant benefits in the treatment of cancer. (BELG J MED ONCOL 2012;6:188–193)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
